CELC vs NVS: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
NVS is the larger of the two ($286.41B market cap): the incumbent the market prices for continued execution (15.27x forward earnings, beta 0.45). CELC is the smaller challenger ($2.65B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, CELC fits: analysts expect its revenue to rise 1981% next year, against 7% for NVS. If you believe in profit, NVS fits: it is expected to make money next year (15.27x forward earnings), while CELC is still expected to post a loss.
CELC vs NVS: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CELC | NVS | What it tells you |
|---|---|---|---|
| Market cap | $2.65B | $286.41B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -10,835.00 | 15.27 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.13 | 0.45 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 1% of range | 58% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how CELC and NVS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CELC and NVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CELC and NVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Celcuity (CELC) do?
Celcuity Inc. is a Minneapolis-based biotechnology company focused on targeted therapies for solid tumors. Its lead product, gedatolisib, is a pan-PI3K/AKT/mTOR (PAM) inhibitor for HR+/HER2- advanced breast cancer. Unlike single-node inhibitors such as alpelisib, capivasertib, and everolimus, gedatolisib is designed to block the whole pathway at once. The registrational Phase 3 VIKTORIA-1 trial hit its primary endpoint, with gedatolisib combination regimens roughly doubling progression-free survival versus alpelisib plus fulvestrant in the PIK3CA-mutant cohort, results presented at ASCO. On July 14, 2026, three days ahead of its PDUFA goal date, the FDA approved gedatolisib as REVTORPYK for adults with HR+/HER2-, PIK3CA wild-type, locally advanced or metastatic breast cancer that progressed after at least one line of endocrine therapy in the metastatic setting, used with fulvestrant with or without palbociclib. Celcuity submitted a supplemental NDA for the PIK3CA-mutant population in August 2026, announced US commercial availability on September 30, 2026, and on November 9, 2026 said the FDA had accepted the sNDA with a PDUFA goal date of June 25, 2027.
What does Novartis AG (NVS) do?
Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025. Revenue was about $56.7 billion in 2025, roughly 10% above 2024, and trailing twelve-month revenue is about $57.4 billion with net income near $10.0 billion.
CELC vs NVS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- CELC drivers: REVTORPYK launch execution; The PIK3CA-mutant label.
- NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Celcuity is still essentially a single-product company, so a slow launch, a delay or narrow outcome on the PIK3CA-mutant sNDA (goal date June 25, 2027), or disappointing later cohort data could sharply reduce the value the market assigns. For NVS, the dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed.
CELC or NVS: which should you pick?
If the story you believe is CELC's (REVTORPYK launch execution), CELC is the more direct way to own it; if it is NVS's (Priority growth brands offsetting the cliff), NVS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CELC and NVS guides.
CELC vs NVS: the full fundamentals
CELC. Because Celcuity has only just begun selling REVTORPYK, standard multiples like price-to-earnings or price-to-sales still do not apply, and the market cap of about $2.7 billion reflects the expected value of the launch and label expansion. Debt of about $755 million now exceeds cash of about $643 million, and management expects the cash to fund operations through 2029. Analysts' mean target near $151 across 13 analysts sits far above the November 20, 2026 price of $54.42, a gap that reflects how differently forecasts and the market are reading the launch.
NVS. At about $152, NVS trades near 29 times trailing earnings but only about 15 times forward estimates, a gap that widened after a third quarter in which reported profit fell to about $1.2 billion while core EPS beat. Analysts expect EPS of about $9.07 in 2026 and $9.93 in 2027. The analyst mean target of roughly $157 sits close to the current price, so how fast the growth brands keep absorbing the generic erosion, and the run of pipeline readouts into 2027, matter more than any single trailing figure. Figures are approximate and tied to the asOf date; verify live numbers before acting.
Headline figures (approximate, November 2026): CELC shows revenue (ttm) ~$0 (first shipments September 30, 2026); Q4 2026 consensus ~$13.6M, market cap ~$2.7B, share price (nov 20, 2026) ~$54, down ~46% YTD, q3 2026 net loss / adjusted eps ~$73.3M / -$1.21 vs -$1.53 estimate; NVS shows revenue (ttm) ~$57.4B; Q3 2026 revenue ~$15.03B, up ~5% year over year, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix offsetting Entresto's generic decline, margins (ttm) ~75% gross, ~34% operating, ~17.5% net, net income (ttm) ~$10.0B.
The bottom line: CELC vs NVS
CELC and NVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CELC and NVS exposure against your real portfolio. It is not an investment adviser.
Wondering how CELC or NVS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Celcuity
Ask Walnut's AI anything about CELC and see how it fits what you own.
FAQ
What is the difference between CELC and NVS?
+
Celcuity Inc. Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CELC or NVS the better stock?
+
Neither is universally better. NVS is the larger incumbent; CELC is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CELC or NVS?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CELC and NVS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CELC vs NVS?
+
CELC: Celcuity is still essentially a single-product company, so a slow launch, a delay or narrow outcome on the PIK3CA-mutant sNDA (goal date June 25, 2027), or disappointing later cohort data could sharply reduce the value the market assigns. The stock fell about 17% in the month to November 20, 2026 and is down about 46% for the year despite approval and an accepted second filing, which shows how harshly it is being judged on early commercial signals. It lost about $256 million over the trailing twelve months, spending is rising with the launch, and stockholders' equity turned negative at September 30, 2026. The June 2026 convertible offering removed near-term funding pressure (about $643 million of cash at September 30, a runway management puts through 2029), but it also added about $575 million of convertible debt that can dilute holders if converted at about $124.53 a share, and total debt on the balance sheet is about $755 million. Commercial uptake faces entrenched and newly approved competitors, payer and pricing pressure, and the operational challenge of a first launch. The stock has been volatile and can gap on single events, which is characteristic of small biotech rather than a defect specific to this name. NVS: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. Analysts expect 2026 EPS to be about flat before rising about 10% in 2027, and reported earnings fell about 69% year over year in the latest quarter. Pipeline risk is structural because late-stage trials can fail and regulators can reject or delay approvals, turning expected future revenue into a write-off, as pelacarsen's failed HORIZON outcomes trial did in 2026. Large acquisitions such as Avidity add integration and financing risk and raised debt, which stood at about $48 billion against about $8.9 billion of cash at September 30, 2026. US drug-pricing policy, potential pharmaceutical tariffs, and pricing pressure are outside the company's control and could compress margins, and in November 2026 the CEO warned that US limits on investment in Chinese biotech could hurt drug development. Because NVS is a Swiss ADR, US investors also carry dollar-versus-Swiss-franc currency risk, and Swiss dividend withholding tax reduces net income for some holders. Concentration in a handful of growth drugs means a single clinical or commercial setback can move the stock.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CELC or NVS; figures are approximate and dated (as of November 2026). Verify current data before investing.